Fat particles could be key to treating metabolic brain disorders

Publicly released:
Australia; QLD
Hippocampal neurons (magenta), labelled for DDHD2 (cyan) and endomembranes (yellow). Photo by UQ
Hippocampal neurons (magenta), labelled for DDHD2 (cyan) and endomembranes (yellow). Photo by UQ

Evidence challenging the long-held assumption that neuronal function in the brain is solely powered by sugars has given researchers new hope of treating debilitating brain disorders.

Media release

From: The University of Queensland

Evidence challenging the long-held assumption that neuronal function in the brain is solely powered by sugars has given researchers new hope of treating debilitating brain disorders.

A University of Queensland study led by Dr Merja Joensuu showed that neurons also use fats for fuel as they fire off the signals for human thought and movement.

“For decades, it was widely accepted that neurons relied exclusively on glucose to fuel their functions in the brain,” Dr Joensuu said.

“But our research shows fats are undoubtedly a crucial part of the neuron’s energy metabolism in the brain and could be a key to repairing and restoring function when it breaks down.”

Dr Joensuu from the Australian Institute for Bioengineering and Nanotechnology along with lab members PhD candidate Nyakuoy Yak and Dr Saber Abd Elkader from UQ’s Queensland Brain Institute set out to examine the relationship of a particular gene (DDHD2) to hereditary spastic paraplegia 54 (HSP54).

Dr Joensuu said the loss of DDHD2 gene function was known to disturb the brain’s fat balance, which ultimately heralded the onset of HSP54.

“We discovered that neurons use small fat molecules, called saturated free fatty acids, produced by DDHD2 for energy to sustain neuronal communication,” Dr Joensuu said.

“Understanding the alternative brain fuel could help unlock new and more effective ways to treat energy-related brain disorders and neurodegenerative conditions.”

Dr Joensuu said the research laid the groundwork to develop a potential therapeutic for HSP54, and provides hope for other metabolic brain disorders and conditions previously thought untreatable.

“We found that activated fatty acid supplements restored energy production and normal function even in neurons with the faulty DDHD2 gene in animal models, after an increase in sugars had proven ineffective,” Dr Joensuu said.

“This was a huge paradigm shift. It showed that the healthy neurons in the brain produce saturated fatty acids that they use for fuel, and in conditions like HSP54, where this fatty acid energy pathway is faulty, the neuronal energy and damages could be repaired with fatty acid supplements.

“Given the brain’s metabolic vulnerability, and the metabolic changes in conditions like Alzheimer’s disease, this discovery could be the missing piece of the puzzle for a number of debilitating illnesses.”

Dr Joensuu said the next stage of the research is to assess the therapeutic efficacy and safety of the activated fatty acids in preclinical studies, an important step toward clinical trials, and to determine whether this brain energy pathway also plays a role in other metabolic brain diseases.

The research has been published in Nature Metabolism. 

Other contributors were based at the University of Helsinki, the University of Oslo, Assiut University, and at -omics data analysis firm i-Synapse.

Multimedia

Dr Merja Joensuu
Dr Merja Joensuu
Dr Merja Joensuu 2
Dr Merja Joensuu 2
Dr Merja Joensuu and PhD scholar Nyakuoy Yak
Dr Merja Joensuu and PhD scholar Nyakuoy Yak

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Springer Nature, Web page The URL will go live after the embargo lifts.
Journal/
conference:
Nature Metabolism
Research:Paper
Organisation/s: Australian Institute for Bioengineering and Nanotechnology (AIBN), Queensland Brain Institute
Funder: This work is supported by The UQs Amplify fellowship to M.J., Institutional support from Australian Institute for Bioengineering and Nanotechnology, and a generous donation from Bruce and Anthea McBryde, as well as the Academy of Finland (335527), the European Union’s Horizon Europe Research and Innovation Program (101057553), the Helsinki Institute for Life Sciences (HiLIFE) and the Sigrid Juselius Foundation Senior Investigator Award to G.B. V.A. holds an Australian Research Council (ARC) Future Fellowship (FT220100485). X.L.H.Y. is supported by the Ian Lindenmayer PhD Top-up Scholarship, N.Y. by WestPac Future Leaders Scholarship and S.H.S., N.Y. and X.L.H.Y. by The Australian Government Research Training Program (RTP) Scholarships. S.E. and I.H. are supported by a doctoral programme in drug research at the University of Helsinki. Q-MAP is supported by Bioplatforms Australia, an NCRIS-funded initiative. This work was supported by a Stafford Fox senior research fellowship and an ARC Future Fellowship (to S.Z.). M.A. is supported by Sigrid Juselius Foundation, Finnish Parkinson Foundation and Academy of Finland 324177 (FinPharma). T.A.N. is supported by the Core Facilities program of the South-Eastern Norway Regional Health Authority, and the Research Council of Norway INFRASTRUKTUR-program (National Network of Advanced Proteomics Infrastructure, 295910). B.J.B. is supported by the Sigrid Juselius Foundation, National Ataxia Foundation, Lindsey Flynt, Hereditary Neuropathy Foundation, Research Council of Finland. This work was also supported by ARC Linkage Infrastructure, Equipment and Facilities grants (LE130100078 and LE230100048).
Media Contact/s
Contact details are only visible to registered journalists.